Canada markets close in 12 minutes

KORU Medical Systems, Inc. (KRMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.3800+0.1300 (+5.78%)
As of 03:46PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close2.2500
Open2.2700
Bid2.3500 x 300
Ask2.4200 x 100
Day's Range2.2700 - 2.4700
52 Week Range1.9780 - 4.2950
Volume65,318
Avg. Volume102,291
Market Cap110.844M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth

    MAHWAH, N.J., May 01, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024.

  • Business Wire

    KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024

    MAHWAH, N.J., April 17, 2024--KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 1, 2024. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financ

  • Business Wire

    KORU Medical Systems Announces Successful Appeal in EU Notified Body Review

    MAHWAH, N.J., April 11, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a successful appeal related to an ongoing audit by its notified body in the EU, The British Standards Institute (BSI).